Clinical trial
A Phase II Study Measuring MRD Negativity After Bispecific T-cell Redirectors Talquetamab and Teclistamab Consolidation in Sequence as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
NCT06505369 is registered in ClinicalTrials.gov with North Estonia Medical Centre as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study Measuring MRD Negativity After Bispecific T-cell Redirectors Talquetamab and Teclistamab Consolidation in Sequence as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
- Lead sponsor
- North Estonia Medical Centre
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 19, 2024
- Completion date
- October 31, 2028
- Enrollment
- 50 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.